作者： 国际糖尿病
SAN FRANCISCO – June 7, 2008 – Researchers from the Joslin Diabetes Center in Boston have shown for the first time that patients with diabetes who enrolled in a short-term weight management program were able to maintain the weight loss they achieved during the program on their own long-term.
来自波士顿Joslin 糖尿病中心的研究人员首次披露对于糖尿病患者进行一项短期体重治疗计划，则可以在治疗后的长时期内保持此种治疗带来的体重减轻。
A study presented today at the American Diabetes Association’s 68th Scientific Sessions showed patients with diabetes enrolled in the Weight Achievement and Intensive Treatment (Why WAIT) program lost on average 24.6 pounds or 10.3 percent of their initial body weight during the 12-week program. At the conclusion of a one-year of follow-up period, the average weight loss was 18.2 pounds or 7.6 percent of initial body weight.
今天在美国糖尿病学会第68次科学年会上报道的一项研究显示，那些参与一项名为体重控制和强化治疗（Why WAIT）计划的糖尿病患者经过为期12周的干预平均能够减轻24.6磅体重或较原始体重减少10.3%。在该计划结束1年后进行的随访中发现，这些病人的体重平均较原先减轻18.2磅或7.6%。
“People have been waiting to see a longer term result of this novel program,” said Osama Hamdy, M.D., Ph.D., director of the clinical obesity program at Joslin and the study’s lead investigator. “Most people think that positive results of clinical trials around weight reduction in people with diabetes can not be replicated in the real world and cannot give similar long-term results. This is going to change the way we treat diabetes and encourage us to move toward weight-based diabetes management rather than adding more medications.”
Joslin临床肥胖研究中心的主管，同时也是这项研究计划的首席研究者Osama Hamdy博士说：人们还将期待这项新研究的进一步后续研究报道。许多人认为那些有关糖尿病患者体重控制的临床研究阳性结果在实际工作中无法重复，并同样不能带来相似的长期效应。现在是改变我们糖尿病治疗思路的时候了，并这也将促进我们迈向以体重控制为基础的糖尿病治疗而不是通过增加更多的药物来对于糖尿病进行治疗。
Why WAIT is a 12-week multidisciplinary diabetes weight management program designed for clinical practice and is mostly covered by insurance. The study followed 85 participants during the 12-week program and for a year afterwards when they were on their own.
Why WAIT是一项为期12周的多学科共同参与为临床实践而设计的糖尿病体重控制计划，这项计划的经费支出主要依赖保险。该计划随访了85名受试者，对其进行了12周的治疗并在此后一年内进行随访。
55 percent of participants continued to lose weight over the course of the follow-up period and maintained excellent diabetes and blood pressure control on less medications. In addition, according to Hamdy, patients saved on average $561 per year on diabetes medications alone.
55%的受试者在治疗结束后的时间内继续保持体重不反弹并仍然能够仅凭少量药物达到血糖、血压的理想控制水平。另外，每位病人每年平均减少了糖尿病药物费用支出达561美元。
The Why WAIT program included a change in diabetes medications to enhance weight reduction, structured dietary intervention with fewer than 40 percent of daily calories from carbohydrates and 30 percent of calories from protein and meal replacement drinks, an exercise program with an emphasis on strength training and weekly educational and support sessions
. Why WAIT计划中包括增加促进体重减轻的糖尿病药物治疗，饮食结构调整（每日能量供应的40%来自碳水化合物，30%来自蛋白质，代餐饮料等），一项强调力量训练的运动计划和每周的宣教交流会。
This talk is one of 87 presentations to be delivered by Joslin scientists at the ADA’s Scientific Sessions, Friday, June 6, through Tuesday, June 10 at the Moscone Convention Center in San Francisco, CA. The session, “Obesity-Pathogenesis and Treatment,” is scheduled for Saturday, June 7 from 4:00 – 6:00 p.m. PDT. [Abstract Number 98-OR: “One Year of Follow up after Completion of 12-Week of Multidisciplinary Diabetes Weight Management Program Using the Why WAIT Intervention Model in Routine Diabetes Practice”]
以上这项报告是Joslin科学家们向本次ADA会议提交的87份报告中的一项，本次ADA会议在旧金山的Moscone会议中心举行，日期为6月6日（星期五）至6月10日（星期二）。按照日程安排，“肥胖病因与治疗”会议在6月7日（星期六）的4:00 – 6:00 p.m举行。（摘要编号98-OR：在常规糖尿病实践中采用Why WAIT干预模型的12周多学科糖尿病体重控制计划的一年随访）
来源：国际糖尿病
http://www.idiabetes.com.cn/
